SurgicEye GmbH is a pioneer in 3D intraoperative imaging and fuses expertise in 3D image reconstruction and surgical navigation to create breakthrough tools in the fight against cancer. SurgicEye’s strong clinical expertise and partner institutions enable our products to be seamlessly integrated into existing workflows as part of our efforts to engineer the best possible user experience.

The declipse®SPECT from SurgicEye® is the world’s first CE and FDA certified product for intraoperative 3D imaging of low-energy radioactive labeled structures using existing gamma probe technology. Without adding any additional hardware, the declipse®SPECT goes further and provides localization and guided biopsy of sentinel lymph nodes in breast, head & neck, cervix and prostate cancers and melanoma. Further this technique can be used in order radioguided surgery procedures. declipse®SPECT enables thus these surgeries to be more sensitive, more reliable and less invasive.

Ongoing clinical investigations in other tumor surgery domains promise a wide application domain and huge potential for quality assurance during surgical interventions.


SurgicEye® delivers tumor imaging and navigation solutions, as well as tools and services to provide high quality, customized and affordable patient treatment.


Global solution and service provider in tumor imaging and navigation towards significant improvements in patient care.

This is achieved and maintained by:

  • Frontline research in medical imaging and navigation
  • Development of high quality products
  • Introduction and establishment of new or improved clinical applications
  • Market introduction and sales of innovative imaging and image guided solutions
  • First class service and knowledge in the application domain